A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

Shire

Status: Completed

Conditions: Hereditary Angioedema (HAE)

Study type: Observational

Funder types: Industry

Identifiers

NCT01541423

SHP616-401

0624-401

Details and patient eligibility

About

This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.

Enrollment: 83 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

All patients must:

• Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of angioedema attacks
• Provide written informed consent/assent in compliance with applicable country-specific and local regulations

Exclusion Criteria

All patients must not:

• Be receiving CINRYZE in an investigational study
• Be receiving another HAE therapy as part of a clinical trial